News

Premier Inc. (NASDAQ: PINC), through its ProvideGx^® program, has partnered with Somerset Pharma, LLC., to supply sulfamethoxazole/trimethoprim, an antibiotic combination used to treat respiratory

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, announced that the U.S. Food

Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today announced a data licensing agreement with the National Institutes of Health (NIH). Under the terms of the agreement

Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2020, highlighting revenue growth and financial strength as well as the advancement of the company’s clinical

Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, has enhanced its crisis forecasting and planning technology to predict the COVID-19 census for any U.S. hospital on a given

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that it will

Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2020 fourth quarter and full year on Tuesday, August 25, 2020, at approximately 6:30 a.m. EDT. The

Novocure (NASDAQ:NVCR) announced today the recipients of the AACR-Novocure Grants for Tumor Treating Fields Research program. The program represents a joint effort between Novocure and the American

Premier Inc. (NASDAQ: PINC) today provided the U.S. Food and Drug Administration (FDA) and the U.S. Drug Enforcement Administration (DEA) with a list of reforms and regulatory waivers that the

Novocure (NASDAQ: NVCR) announced today that the first patient has been enrolled in its EF-33 phase 2 pilot trial of Tumor Treating Fields delivered utilizing high-intensity arrays in patients with

Virginia Mason Health System, a leading non-profit regional healthcare system serving the Pacific Northwest, and Premier Inc. (NASDAQ: PINC), a healthcare improvement company, have partnered to

Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with MSD (a tradename of Merck & Co., Inc.), through a subsidiary, to develop Tumor Treating

Premier Inc. (NASDAQ: PINC), through its ProvideGx™ program, has partnered with Fresenius Kabi to supply Diprivan^® (propofol) injectable emulsion, USP to healthcare providers, helping to stabilize

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and Atreca, Inc. (Atreca)

Novocure (NASDAQ: NVCR) today announced that over 100 physicians from more than 50 cancer treatment centers in the U.S. are now certified to prescribe Optune Lua, which is approved for the

Novocure (NASDAQ: NVCR) today announced that the last patient has been enrolled in the HEPANOVA trial, a phase 2 pilot trial testing Tumor Treating Fields in combination with sorafenib in patients

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2020 on Thursday, July 30, 2020, before the U.S. financial markets open. Novocure’s management

Nearly 90 percent of healthcare providers are contributing to stockpiles of critical medical supplies and drugs intended to last as long as 90 days, according to a recent survey conducted by

Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today released survey results finding that the majority of alternate site providers, including senior living facilities

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced the

Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today debuted Intersectta®, a new oncology-focused group purchasing organization (GPO) to source cancer and other specialty

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) (the “Company” or “Acadia”) announced today the pricing of its previously announced private offering (the “Offering”) of $450 million in aggregate

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) (the “Company” or “Acadia”) announced today that it has launched a private offering (the “Offering”) of senior notes due 2028 (the “Notes”), subject

Premier Inc. (NASDAQ: PINC) today provided the U.S. Department of Health and Human Services (HHS) and Congress with a list of 24 regulatory waivers that should be made permanent as the COVID-19

Novocure (NASDAQ: NVCR) today announced the launch of MyLink, a new tool that allows patients to download their Optune usage data from the comfort of home without the need for an in-person visit by